Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 5, 2018
http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12529525&doc=4
AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

   001-33497
  71-0869350
 (Commission File Number)
(IRS Employer Identification No.)

 
 
1 Cedar Brook Drive, Cranbury, NJ
08512
  (Address of Principal Executive Offices)    
     (Zip Code)
                  
Registrant’s telephone number, including area code: (609) 662-2000

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o







Item 2.02 Results of Operations and Financial Condition

On November 5, 2018, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third fiscal quarter, ended September 30, 2018. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on November 5, 2018 to discuss its third quarter results of operations. A copy of the conference call presentation materials is also attached hereto as Exhibit 99.2.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 

Item 9.01 Financial Statements and Exhibits
(d) Exhibits:

Exhibit No.
Description









SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
AMICUS THERAPEUTICS, INC.
Date: November 5, 2018
By: /s/ Ellen S. Rosenberg
 
Name: Ellen S. Rosenberg
 
Title: General Counsel and Corporate Secretary



exhibit991
Exhibit 99.1 Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates U.S. Galafold® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued International Growth - 500+ International Fabry Patients Now on Galafold Reaffirming Higher End of FY18 Revenue Guidance of $80M-$90M – Balance Sheet Strength Sufficient to Fund Operations into at least 2021 Gene Therapy Pipeline Provides 14 New Programs and Future Growth Platform Conference Call and Webcast Today at 8:30am ET CRANBURY, NJ, November 5, 2018 – Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2018. The Company also summarized recent program updates, reiterated its full-year 2018 revenue guidance and reduced its net cash spend guidance for the year. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “The third quarter marked a major transformation for Amicus that brings us several steps closer toward our 2023 vision to treat at least 5,000 patients and to achieve $1 billion in annual global revenue. In the last three months, we received our first U.S. drug approval for Galafold, expanded our pipeline to include 14 new gene therapy programs for rare metabolic diseases, and presented positive 18-month data for our differentiated Pompe treatment paradigm. With a strong revenue base and $500M+ peak sales opportunity for Galafold, as well as $564 million in cash, we have never been in a stronger position to advance our robust portfolio to drive significant value for shareholders and the patient communities that we serve.” Third Quarter 2018 Financial Results and Full-Year 2018 Financial Guidance  Total revenue in the third quarter 2018 was $20.6 million, a year-over-year increase of 89% from total revenue of $10.9 million in the third quarter of 2017. Third quarter revenue was impacted by uneven ordering patterns over the summer months in Europe.  Cash, cash equivalents, and marketable securities totaled $564.4 million at September 30, 2018, compared to $358.6 million at December 31, 2017.  Total operating expenses for the third quarter 2018 were $172.5 million compared to $284.3 million in the third quarter 2017. The decrease is due primarily to a non-cash impairment charge incurred in 3Q17, partially offset by an upfront payment of $100 million for the Celenex asset acquisition which was reflected in the third quarter 2018 as a research and development expense.  Net cash spend was $35.2 million for the third quarter 2018. Net loss was $159.2 million, or $0.84 per share, for the third quarter 2018 compared to a net loss of $111.7 million, or $0.69 per share, for the third quarter 2017. Total net operating expenses were $172.5 million, which includes the $100 million Celenex asset acquisition cost. “We are very pleased with the momentum of the global Galafold launch,” said Bradley L. Campbell, President and Chief Operating Officer of Amicus Therapeutics. “We see continued strong uptake and growth, along with very high compliance and adherence to this new oral Fabry treatment option, in both patients who are ERT-experienced and an increasing number who are ERT-treatment naïve in Europe. As


 
anticipated, quarter-over-quarter revenue reflect some uneven ordering patterns as well as a rising number of extended, 90-day prescriptions as we headed into the summer months, which have normalized since the start of the fourth quarter. These adoption trends may reflect the emerging Fabry treatment paradigm with a stable oral medication that can be taken during summer travels and on holidays. Japan is also off to a solid start, now with a double-digit number of patient prescriptions. Importantly, the first 12 weeks of the U.S. launch have significantly exceeded our expectations. With more than 100 individual prescriptions for Galafold in the U.S., we are seeing robust patient demand from a broad prescriber base of more than 40 Fabry physicians. Given this global momentum, we are confident in meeting the higher end of our full-year 2018 guidance and setting a solid foundation for 2019.” 2018 Financial Guidance For the full-year 2018 the Company reiterated its total Galafold revenue guidance to $80 to $90 million. This reflects global revenue from all expected 2018 commercial markets. The Company is lowering its full- year 2018 net cash spend to $190 to $210 million from the previous range of $220 to $250 million. The current cash position, including Galafold revenues, is sufficient to fund ongoing operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company’s future capital requirements. Program Highlights Galafold (Migalastat) Oral Precision Medicine for Fabry Disease Galafold is an oral precision medicine for Fabry disease approved in the EU and other geographies to treat Fabry disease in patients 16 years or older who have amenable genetic mutations. The U.S. FDA approved Galafold under Subpart H for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. For patients who are not suitable for treatment with Galafold on the basis of their genetic mutations, or variants, Amicus is advancing a next-generation gene therapy. Global Galafold Updates:  U.S. FDA approval on August 10, 2018  U.S. launch tracking ahead of internal expectations with 103 new patient prescriptions, also known as patient referral forms (PRFs), as of October 31, 2018. Time to shipment is approximately 60 days, limiting 2018 revenue impact but providing a strong foundation for 2019.  Launched in Australia on November 1 following formal listing on life saving drugs program  Pricing and reimbursement secured in 22 countries  Approvals secured in eight total geographies including Australia, Canada, EU, Israel, Japan, South Korea, Switzerland, and United States and pending in Taiwan AT-GAA for Pompe Disease AT-GAA is a novel treatment paradigm that consists of ATB200, a unique recombinant human acid alpha- glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose 6-phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone to stabilize ATB200 while in the circulation to deliver active therapeutic enzyme. Positive results from a global Phase 1/2 clinical study (ATB200-02) have shown consistent and durable responses across key measures of safety, functional outcomes and biomarkers in both ERT-switch and ERT-naïve Pompe patients following up to 18 months of treatment with AT-GAA. The Company’s strategy is to enhance the body of clinical data for AT-GAA in ongoing studies and the upcoming pivotal study (PROPEL, also referred to as ATB200-03) to deliver this potential new therapy to as many people living with Pompe disease as soon as possible. Recent and Anticipated AT-GAA Program Milestones:  Positive 18-month data from ATB200-02 Phase 1/2 clinical study at World Muscle Society  1,000L GMP material released for pivotal study.


 
 Initiation of PROPEL pivotal study to support full approval in U.S. and EU, and other geographies (4Q18)  Completion of retrospective natural history study in approximately 100 ERT-treated Pompe patients (4Q18)  Additional ATB200-02 study data from up to 10 additional ERT-switch patients in Cohort 4 (2019)  Initiation of studies in additional patient populations, including pediatric patients (2019)  Update on long-term manufacturing strategy As part of the Company’s long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe community, Amicus is also advancing a next-generation gene therapy as a potential cure for Pompe disease. Gene Therapy Portfolio: 14 New Programs for Rare Metabolic Diseases During the third quarter and early fourth quarter, Amicus expanded its pipline [link here] to include 14 new gene therapy programs and future growth platform for rare metabolic diseases. The Company acquired 10 preclinical and clinical stage adeno associated virus (AAV) programs (intrathecal delivery) for neurologic lysosomal storage disorders (LSDs) currently in development at Nationwide Children’s Hospital. In collaboration with the University of Pennsylvania, the Company is advancing four next-generation AAV gene therapies for Fabry disease, Pompe disease, CDKL5 deficiency disorder (CDD) and one additional undisclosed rare metabolic disorder. Additional details are available in the third quarter 2018 results slide presentation at www.amicusrx.com in the Investors & Media section [link here]. Gene Therapy Pipeline Highlights:  Batten Disease: Compelling proof-of-concept demonstrated in preclinical studies in CLN6, CLN3, and CLN8, as well as initial clinical safety and efficacy in a Phase 1/2 study in patients with CLN6.  Pompe Disease: Early proof-of-principle for Amicus DNA constructs for an optimized gene therapy to address all aspects of Pompe disease including the central nervous sytem, heart, and muscles.  Fabry Disease: Early proof-of-principle for Amicus DNA constructs for an optimized gene therapy to deliver stable, active enzyme to lysosomes. Upcoming Gene Therapy Pipeline Milestones in 2018 and 2019:  First Patient in CLN3 Batten disease Phase 1/2 Study (4Q18)  Completion of enrollment in CLN6 Batten disease Phase 1/2 study  Preliminary data from CLN6 Batten disease Phase 1/2 study  Enrollment of full initial cohort in CLN3 Batten disease Phase 1/2 study  Preclinical data for next-generation gene therapies for Fabry, Pompe and CDD  Preclinical work across additional neurologic LSDs Conference Call and Webcast Amicus Therapeutics will host a conference call and audio webcast today, November 5, 2018, at 8:30 a.m. ET to discuss the third quarter 2018 financial results and corporate updates. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 2292105. An audio webcast and slide presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/ and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on November 5, 2018. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404- 537-3406 (international); conference ID: 2292105.


 
About Galafold GalafoldTM (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland and the U.S. U. S. INDICATIONS AND USAGE Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. U.S. IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia. USE IN SPECIFIC POPULATIONS There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1- 800-FDA-1088 or www.fda.gov/medwatch. For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf. EU Important Safety Information Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.  Galafold is not intended for concomitant use with enzyme replacement therapy.  Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children 0–15 years of age have not yet been established.  No dosage adjustments are required in patients with hepatic impairment or in the elderly population.  There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.  While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk.


 
 Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.  It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold.  OVERDOSE: General medical care is recommended in the case of Galafold overdose.  The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.  Call your doctor for medical advice about side effects. For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2017 as well as our Quarterly Report on Form 10-Q for the quarter September 30, 2018 to be filed November 6, 2018 with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


 
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino, IRC Vice President, Investor Relations & Corporate Communications spellegrino@amicusrx.com (609) 662-5044 Media: Pure Communications Jennifer Paganelli jpaganelli@purecommunications.com (347) 658-8290


 
TABLE 1 Amicus Therapeutics, Inc. Consolidated Statements of Operations (in thousands, except share and per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Revenue: Net product sales $ 20,596 $ 10,874 $ 58,601 $ 22,201 Cost of goods sold 4,310 1,790 10,060 3,626 Gross Profit 16,286 9,084 48,541 18,575 Operating Expenses: Research and development 138,227 40,641 213,685 103,502 Selling, general and administrative 31,867 21,647 88,435 60,090 Changes in fair value of contingent 1,300 (244,250) 2,700 (238,622) consideration payable Loss on impairment of assets — 465,427 — 465,427 Depreciation 1,073 851 3,015 2,486 Total operating expenses 172,467 284,316 307,835 392,883 Loss from operations (156,181 ) (275,232 ) (259,294 ) (374,308) Other income (expense): Interest income 2,721 1,190 7,371 2,702 Interest expense (4,715 ) (4,351 ) (13,763 ) (12,820) Change in fair value of derivatives — — — (2,739 ) 163 Other (expense) income (1,039 ) 2,044 (3,593 ) 4,891 Loss before income tax (159,214 ) (276,349 ) (272,018 ) (379,372) Income tax benefit 51 164,683 1,104 164,578 Net loss attributable to common stockholders $ (159,163 ) $ (111,666 ) $ (270,914 ) $ (214,794) Net loss attributable to common stockholders per $ (0.84 ) $ (0.69 ) $ (1.47 ) $ (1.44) common share — basic and diluted Weighted-average common shares 189,162,841 160,796,841 184,606,790 148,963,864 outstanding — basic and diluted


 
TABLE 2 Amicus Therapeutics, Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, December 31, 2018 2017 Assets Current assets: Cash and cash equivalents $ 201,827 $ 49,060 Investments in marketable securities 362,556 309,502 Accounts receivable 14,189 9,464 Inventories 6,311 4,623 Prepaid expenses and other current assets 16,151 19,316 Total current assets 601,034 391,965 Property and equipment, less accumulated depreciation of $15,483 and $12,515 at September 30, 2018 and December 31, 2017, respectively 10,659 9,062 In-process research & development 23,000 23,000 Goodwill 197,797 197,797 Other non-current assets 6,099 5,200 Total Assets $ 838,589 $ 627,024 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable, accrued expenses, and other current liabilities $ 54,330 $ 53,890 Deferred reimbursements 2,750 7,750 Contingent consideration payable 8,800 8,400 Total current liabilities 65,880 70,040 Deferred reimbursements 14,156 14,156 Convertible notes 172,186 164,167 Senior secured term loan 146,622 — Contingent consideration payable 19,300 17,000 Deferred income taxes 6,465 6,465 Other non-current liabilites 3,029 2,346 Total liabilities 427,638 274,174 Commitments and contingencies Stockholders’ equity: Common stock, $0.01 par value, 500,000,000 and 250,000,000 shares authorized, 189,254,341 and 166,989,790 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 1,941 1,721 Additional paid-in capital 1,731,174 1,400,758 Accumulated other comprehensive loss: Foreign currency translation adjustment (875 ) (1,659) Unrealized gain on available-for-sale securities (211 ) (436) Warrants 13,063 16,076 Accumulated deficit (1,334,141 ) (1,063,610) Total stockholders’ equity 410,951 352,850 Total Liabilities and Stockholders’ Equity $ 838,589 $ 627,024 FOLD–G


 
exhibit992
Exhibit 99.2 3Q18 Financial Results & Corporate Highlights November 5, 2018


 
2 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2017 as well as our Quarterly Report on Form 10-Q for the quarter September 30, 2018 to be filed November 6, 2018 with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


 
Introduction 3 Amicus Today PORTFOLIO 500+ of 15 programs for rare EMPLOYEES metabolic diseases globally BIOLOGICS AT-GAA* PLATFORM Investigational Leading Expertise in Protein Engineering Therapy for Lysosomal & Glycobiology Pompe Entering Phase 3 Storage GLOBAL Disorders ~$564M Gene Therapy FOOTPRINT Cash in 27 countries (9/30/18) Platforms * AT-GAA, also known as ATB200/AT2221


 
Introduction 4 Corporate Highlights: 3Q18 and Early 4Q18 » Well Capitalized to Advance Toward 2023 Vision: 5,000+ Patients & $1B+ in Revenue » Current Cash Position is Sufficient to Fund Operations into at least 2021 » Galafold: International Growth and Strong U.S. Launch Momentum o U.S. launch exceeding expectations following August 2018 approval; now reimbursed in 22 countries o 3Q18 revenue of $20.6M – on track to meet $80M-90M FY18 guidance range o $500M+ peak revenue potential; $1B+ cumulative revenue from 2019E-2023E to drive R&D engine » AT-GAA: Positive 18-month Data Presented World Muscle Society (October 2018) o Highly differentiated ERT with potential to be the future standard of care o On track to initiate pivotal study by YE18 o $1B+ peak revenue potential » NEW Gene Therapy Portfolio for 14 Rare Metabolic Diseases o Industry leading Batten disease portfolio: Two clinical stage programs (CLN6 and CLN3); One preclinical (CLN8) o Preclinical AAV (intrathecal) gene therapy programs for 7 additional neurologic LSDs o Next-generation preclinical gene therapies for Fabry, Pompe, CDKL5 and one other indication o $1B+ peak revenue potential


 
Introduction 5 Robust Rare Disease Portfolio DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold™ (Migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Other Gene Therapy Programs CLN6 Batten Disease NCH CLN3 Batten Disease NCH CLN8 Batten Disease NCH Advancing one of Neimann-Pick Type C (NPC) NCH the most robust Wolman Disease NCH rare disease Tay-Sachs Disease NCH portfolios in Multiple Other CNS LSDs NCH biotechnology CDKL5 Deficiency Disorder Gene Therapy / ERT PENN Other PENN


 
Galafold® (Migalastat) Precision Medicine for Fabry Disease


 
Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of November 5, 2018) $20.6M $80-90M 3Q18 Galafold FY18 Global Galafold FIRST Oral Precision Revenue Rev. Guidance Medicine for Fabry Disease Patients with 1 22 Pending Countries with Amenable Variants Regulatory Pricing & Approval: Reimbursement Taiwan 8 348 Regulatory Approvals: Amenable Australia, Canada, EU, Variants in U.S. Israel, Japan, S. Korea, Switzerland , U.S. Label


 
Galafold: Precision Medicine for Fabry Disease 8 International Update (as of October 31, 2018) Continuing to Execute on Our Strategy with High Compliance and Adherence Among 500+ International Patients on Galafold Current estimated MARKET DYNAMICS mkt share in EU5* of treated amenable patients • Continued strong uptake and growth in ERT-switch patients; increasing number of previously untreated patients • Very high rates of adherence and compliance (>90%) Galafold ERT • Balanced mix of males and females, ~50% ~50% classic and late-onset patients • Oral ROA allows for new ordering patterns • Continued high interest from physician community • 145 HCPs attended inaugural Amicus Fabry Connections meeting in Madrid, Spain *Market share assumptions based on estimated number of treated amenable patients in EU5 as of October 2018


 
Galafold: Precision Medicine for Fabry Disease 9 Key U.S. Launch Metric – Individual Prescriptions (Patient Referral Forms) 103 Individual Prescriptions (10/31/18) Significantly Exceeds Internal Forecast and Provides Strong Foundation for 2019 Individual Prescriptions Actual PRFs 103 Market Dynamics • Strong patient and physician demand 75 • High conversion of study patients 64 Forecast • Growing prescriber base of 40+ physicians 66 • Patient demographics in line with launch strategy 54 • ~60 day average PRF to shipment 24 43 limits FY18 impact 32 • Solid foundation for 2019 20 August 30 September 30 October 31 November 30 December 31


 
Galafold: Precision Medicine for Fabry Disease 10 Galafold Success and FY18 Galafold Revenue Guidance On Track to Achieve Higher End of FY2018 Revenue Guidance of $80-$90M $80-$90M Q3* $20.6M $36.9M Q2 $21.3M $10.9M $14.6M $7.2M $4.2M Q1 $16.7M 1Q17 2Q17 3Q17 4Q17 FY17 FY18E *QoQ revenue reflects new ordering patterns


 
Financial Summary


 
Financial Summary 12 3Q18 Select Financial Results 3Q18 Revenue of $20.6M Primarily from International Galafold Sales Sept. 30, 2018 (in thousands, except per share data) Sept. 30, 2017 Product revenue 20,596 10,874 Cost of goods sold 4,310 1,790 R&D expense 138,227* 40,641 SG&A expense 31,867 21,647 Changes in fair value of contingent consideration 1,300 (244,250) Loss on impairment of assets - 465,427 Loss from operations (156,181) (275,232) Income tax benefit 51 164,683 Net loss (159,163) (111,666) Net loss per share (0.84) (0.69) *Inclusive of upfront payment of $100 million for the Celenex asset acquisition


 
Financial Summary 13 Financial Summary & Guidance Strong Balance Sheet with $564M Cash at 9/30/18 - Cash Runway into at Least 2021 FINANCIAL POSITION September 30, 2018 Cash $564M Debt $319M Cash Runway1 Into at least 2021 CAPITALIZATION Shares Outstanding2 189,254,341 FINANCIAL GUIDANCE FY18 Net Cash Spend Guidance $190M-$210M Galafold Revenue Guidance $80-$90M 1Based on existing operating plan. 2Includes shares from the February 2018 equity offering


 
AT-GAA Novel ERT for Pompe Disease


 
Pompe 18 Month Data: ATB200-02 Phase 1/2 Clinical Study of AT-GAA (ATB200/AT2221) 15 AT-GAA 18-Month Clinical Data Summary (ATB200-02 Study) Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers in both ERT-Switch and ERT-Naïve Pompe Patients out to Month 18 • 6-minute walk test (6MWT) showed continued benefit in ERT-naïve and ERT-switch patients • Timed motor function tests generally consistent with 6MWT results in both ambulatory cohorts • Muscle strength increased in all cohorts, including nonambulatory ERT-switch patients • Pulmonary function – Forced vital capacity (FVC), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) generally increased in ERT-naive patients – FVC, MIP, and MEP were generally stable in ERT-switch patients • Fatigue severity scale – Improvement in fatigue score was observed in all cohorts • Biomarkers and safety – Creatine kinase (CK) and urine hexose tetrasaccharide (Hex4) levels decreased in all cohorts – AT-GAA (ATB200/AT2221) was generally well tolerated – Adverse Events Generally Mild and Transient • Very low rates of IARs (<1%) after 890+ total infusions across all cohorts


 
AT-GAA Novel ERT + Chaperone for Pompe Disease 16 Key Activities in 2018 Significant Progress in Clinical, Regulatory, and GMP Manufacturing Activities in 2018 Year-to-Date Progress CLINICAL MANUFACTURING  Addt’l. Phase 1/2 ATB200-02 extension data presented at WORLDSymposium  Final FDA agreement on comparability between  Addt’l. patients in Phase 1/2 ATB200-02 clinical study 1,000L and 250L GMP scale   Initiation of retrospective natural history of ERT-treated patients German regulatory authorities (BfArM) agreement  on strategy to demonstrate comparability between 18-month data from ATB200-02 clinical study (4Q18) 1,000L and 250L GMP scale  Initiation of larger registration-directed study  Release for clinic of 1,000L GMP commercial scale  Completion of a retrospective natural history study (4Q18) material  Announce plan for long-term commercial REGULATORY manufacturing  EMA: Received Scientific Advice Working Party Guidance  U.S. FDA type C meeting and U.S. update


 
Gene Therapy Pipeline


 
Amicus Gene Therapy Programs 18 Leading Gene Therapy Portfolio in Lysosomal Storage Disorders License Through Nationwide Children’s Hospital and Collaboration with Penn Combine with Successful Amicus Development and Commercial Track Record in LSDs Amicus Gene Therapy Portfolio Ground-Breaking, Clinically Validated Science DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 CLN6 Batten Disease NCH 14 Gene Therapy Programs CLN3 Batten Disease NCH CLN8 Batten Disease NCH Fabry Gene Therapy PENN Expertise and Relationships in Gene Therapy Pompe Gene Therapy PENN Neimann-Pick C NCH Compelling Data in Three Lead Batten Disease Wolman Disease NCH Programs; Earlier-Stage Fabry and Pompe Programs Tay-Sachs NCH Multiple Other CNS LSDs NCH CDKL5 Gene Therapy / ERT PENN Leading Gene Therapy Portfolio in Lysosomal Storage Disorders Other PENN


 
Amicus AAV9 Gene Therapy Programs 19 Platform Proof-of-Concept for Lead Batten Disease Programs CLN6 and CLN3 Programs are Clinical Stage; CLN8 has Definitive Preclinical Efficacy Data in a Mouse Model of Disease – All Following Single AAV Intrathecal Administration P R E C L I N I C A L M O U S E M O D E L D A T A Storage Motor & Safety & Brain GMP IND Preliminary Material & Survival Cognitive Function Expression in NHP Clinical Supply Active Clinical Data Glial Activation CLN6 CLN3 N/A* Pending CLN8 Pending Pending Pending Pending *CLN3 mouse model does not have impaired survival


 
Amicus-Penn Collaboration 20 Amicus Protein Engineering Expertise & Technologies for Gene Therapy Collaboration with Penn to Enable Greater Protein Expression and Delivery at Lower Gene Therapy Doses for Fabry, Pompe, CDKL5 Deficiency Disorder and 1 Additional Indication Increased Protein Increased Protein Improved Protein Expression Secretion Targeting and Stabilization Novel untranslated Effective signal sequences to Targeting moieties sequences to avoid inhibition increase protein expression of initiation and drive & secretion Protein design efficient protein synthesis


 
Closing Remarks John F. Crowley


 
Closing Remarks 22 2018 Key Strategic Priorities On Track to Achieve All FIVE Key Strategic 2018 Priorities Outlined in January 1 Double Galafold (migalastat) revenue to $80-$90M 2 Secure approvals for migalastat in Japan and the U.S.  Achieve clinical, manufacturing and regulatory milestones to advance 3 AT-GAA toward global regulatory submissions and approvals 4 Develop and expand preclinical pipeline to ensure  at least one new clinical program in 2019 5 Maintain financial strength


 
Closing Remarks 23 Amicus Vision: Delivering for Patients and Shareholders To build a top-tier, fully integrated, global biotechnology company whose medicines treat 5,000+ patients with $1B+ in worldwide sales revenue by 2023 >350 Patients* | $36.9M Global Sales 5,000 Patients* | $1B Global Sales YE17 2023 *Clinical & commercial, all figures approximate


 
Thank You